G
Gad Getz
Researcher at Broad Institute
Publications - 627
Citations - 309042
Gad Getz is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 189, co-authored 520 publications receiving 247560 citations. Previous affiliations of Gad Getz include University of Colorado Denver & University of California, San Diego.
Papers
More filters
Proceedings ArticleDOI
Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma
Rachel G. Liao,Peter S. Hammerman,Andrey Sivachenko,Heidi Greulich,Gad Getz,Qingsong Liu,Nathanael S. Gray,Matthew Meyerson +7 more
TL;DR: Data suggest that mutations in the FGFR3 gene are sufficient to transform cells, and this finding, along with recently published data suggesting that FGFR1 amplification is also able to drive lung SCC development, demonstrates that theFGFR family may be a promising therapeutic target in lung S CC.
Journal ArticleDOI
Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
Seth A. Wander,Ofir Cohen,Gabriela N. Johnson,Dewey Kim,Flora Luo,Pingping Mao,Utthara Nayar,Karla Helvie,Lori Marini,Samuel S. Freeman,Gad Getz,Levi A. Garraway,Eric P. Winer,Nan Lin,Nikhil Wagle +14 more
TL;DR: Combining CDK4/6i with endocrine therapy results in prolongation of disease control in HR+ MBC, though resistance invariably occurs.
Journal ArticleDOI
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Ashish Noronha,Nishanth Belugali Nataraj,Joo Sang Lee,Benny Zhitomirsky,Yaara Oren,Sara K. Oster,Moshit Lindzen,Saptaparna Mukherjee,Rainer Will,Soma Ghosh,Arturo Simoni-Nieves,Aakanksha Pathak Sitansu Kumar Verma,Rishita Chatterjee,Simone Borgoni,Welles Robinson,Sanju Sinha,Alexander Brandis,Daniel Lucas Kerr,Wei Wu,Aruna Ramanan Sekar,Suvendu Giri,Young Chul Chung,Diana Drago-Garcia,Brian P. Danysh,Mattia Lauriola,Michelangelo Fiorentino,Andrea Ardizzoni,Moshe Oren,Collin M. Blakely,Jideofor Ezike,Stefan Wiemann,Laxmi Parida,Trever G. Bivona,Rami I. Aqeilan,Joan S. Brugge,Aviv Regev,Gad Getz,Eytan Ruppin,Yosef Yarden +38 more
TL;DR: Treatment of lung cancer with EGFR inhibitors with AXL overexpression cured patient-derived xenografts and uncovered another hypermutator, AXL-driven activation of MYC and increased purine synthesis that is unbalanced by pyrimidines.
Journal ArticleDOI
Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)
Ishwarya Murali,Ishwarya Murali,Siddha Kasar,Siddha Kasar,Emily M. McWilliams,Gilad Itchaki,Svitlana Tyekucheva,Dimitri Livitz,Ignaty Leshchiner,Shuai Dong,Stacey M. Fernandes,Gad Getz,Gad Getz,Amy J. Johnson,Jennifer R. Brown,Jennifer R. Brown,Jennifer R. Brown +16 more
TL;DR: The present study designed to identify mechanisms underlying PI3K inhibitor resistance in CLL through WES, RNAseq and biochemical confirmation, and investigated the role of the ERK/MAPK pathway in idelalisib resistance.
Posted ContentDOI
A deep learning system can accurately classify primary and metastatic cancers based on patterns of passenger mutations
Wei Jiao,Gurnit Atwal,Paz Polak,Rosa Karlic,Edwin Cuppen,A. Danyi,de Ridder J,van Herpen C,Lolkema Mp,Neeltje Steeghs,Gad Getz,Quaid Morris,Lincoln Stein +12 more
TL;DR: A deep learning classifier is trained to predict cancer type based on patterns of somatic passenger mutations detected in whole genome sequencing (WGS) of 2606 tumours representing 24 common cancer types, and surprisingly, adding information on driver mutations reduced classifier accuracy.